Topical and Transdermal

  • William J. McAuley
  • Matthew Traynor
  • Marc B. Brown
Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 11)

Abstract

Formulations designed to be applied to the skin, in particular for the treatment of skin diseases are commonly used for children. There are a number of important issues with regards to the use of these types medicines in the pediatric population in comparison to adults; for example children have a greater risk of experiencing systemic side effects as a result of treatment. This chapter discusses the roles of the different formulations used for topical and transdermal treatment, their design and considerations specifically relevant for the development of these medicines for children.

Keywords

Permeability Toxicity Rubber Testosterone Valerate 

References

  1. 1.
    Bechelli LM, Haddad N, Pimenta WP, Pagnano PMG, Melchior E, Fregnan RC, Zanin LC, Arenas A (1981) Epidemiological survey of skin diseases in school-children living in the Purus valley (Acre state, Amazonia, Brazil). Dermatologica 163(1):78–93PubMedCrossRefGoogle Scholar
  2. 2.
    Dogra S, Kumar B (2003) Epidemiology of skin diseases in school children: a study from northern India. Pediatr Dermatol 20(6):470–473PubMedCrossRefGoogle Scholar
  3. 3.
    Fergusson DM, Dimond ME, Shannon FT (1984) Morbidity during the preschool years. Aust Paediatr J 20(4):281–287PubMedGoogle Scholar
  4. 4.
    Kottenhahn RK, Heck JE (1994) Prevalence of pediatric skin diseases in rural Honduras. Trop Doct 24(2):87–88PubMedGoogle Scholar
  5. 5.
    Mahe A, Prual A, Konate M, Bobin P (1995) Skin diseases of children in Mali – a public-health problem. Trans R Soc Trop Med Hyg 89(5):467–470PubMedCrossRefGoogle Scholar
  6. 6.
    Popescu R, Popescu CM, Williams HC, Forsea D (1999) The prevalence of skin conditions in Romanian school children. Br J Dermatol 140(5):891–896PubMedCrossRefGoogle Scholar
  7. 7.
    Ghodsi SZ, Orawa H, Zouboulis CC (2009) Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 129(9):2136–2141PubMedCrossRefGoogle Scholar
  8. 8.
    Foley P, Zuo YQ, Plunkett A, Marks R (2001) The frequency of common skin conditions in preschool-age children in Australia – atopic dermatitis. Arch Dermatol 137(3):293–300PubMedGoogle Scholar
  9. 9.
    Mar A, Marks R (1999) The descriptive epidemiology of atopic dermatitis in the community. Australas J Dermatol 40(2):73–78PubMedCrossRefGoogle Scholar
  10. 10.
    Peat JK, Vandenberg RH, Green WF, Mellis CM, Leeder SR, Woolcock AJ (1994) Changing prevalence of asthma in Australian children. Br Med J 308(6944):1591–1596CrossRefGoogle Scholar
  11. 11.
    Schultz Larsen F (1993) The epidemiology of atopic dermatitis. In: Burr ML (ed) Epidemiology of clinical allergy. Monographs in allergy. S. Karger AG, Basel, 9–28Google Scholar
  12. 12.
    Walker RB, Warin RP (1956) The incidence of eczema in early childhood. Br J Dermatol 68(5):182–183PubMedCrossRefGoogle Scholar
  13. 13.
    Williams HC (1992) Is the prevalence of atopic-dermatitis increasing. Clin Exp Dermatol 17(6):385–391PubMedCrossRefGoogle Scholar
  14. 14.
    Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG (1994) The prevalence of childhood atopic eczema in a general-population. J Am Acad Dermatol 30(1):35–39PubMedCrossRefGoogle Scholar
  15. 15.
    Correale CE, Walker C, Murphy L, Craig TJ (1999) Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 60(4):1191–1198PubMedGoogle Scholar
  16. 16.
    Ozkaya E (2005) Adult-onset atopic dermatitis. J Am Acad Dermatol 52(4):579–582PubMedCrossRefGoogle Scholar
  17. 17.
    Williams HC, Strachan DP (1998) The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 139(5):834–839PubMedCrossRefGoogle Scholar
  18. 18.
    Lello J, Pearl A, Arroll B, Yallop J, Birchall NM (1995) Prevalence of acne-vulgaris in Auckland senior high-school-students. N Z Med J 108(1004):287–289PubMedGoogle Scholar
  19. 19.
    Lucky AW, Biro FM, Huster GA, Morrison JA, Elder N (1991) Acne-vulgaris in early adolescent boys – correlations with pubertal maturation and age. Arch Dermatol 127(2):210–216PubMedCrossRefGoogle Scholar
  20. 20.
    Rademaker M, Garioch JJ, Simpson NB (1989) Acne in schoolchildren no longer a concern for dermatologists. Br Med J 298(6682):1218–1219CrossRefGoogle Scholar
  21. 21.
    Goulden V, Stables GI, Cunliffe WJ (1999) Prevalence of facial acne in adults. J Am Acad Dermatol 41(4):577–580PubMedGoogle Scholar
  22. 22.
    Jordan WE, Lawson KD, Berg RW, Franxman JJ, Marrer AM (1986) Diaper dermatitis: frequency and severity among a general infant population. Pediatr Dermatol 3(3):198–207PubMedCrossRefGoogle Scholar
  23. 23.
    Philipp R, Hughes A, Golding J (1997) Getting to the bottom of nappy rash. Br J Gen Pract 47(421):493–497PubMedCentralPubMedGoogle Scholar
  24. 24.
    Virgili A, Corazza M, Califano A (1998) Diaper dermatitis in an adult – a case of erythema papuloerosive of Sevestre and Jacquet. J Reprod Med 43(11):949–951PubMedGoogle Scholar
  25. 25.
    Fantl J, Newman D, Colling J et al (1996) Urinary incontinence in adults: acute and chronic management: clinical practice guideline number 2, 1996 update (Report No. 96-0682). Agency for Health Care Policy and Research (AHCPR), RockvilleGoogle Scholar
  26. 26.
    Ward DB, Fleischer AB, Feldman SR, Krowchuk DP (2000) Characterization of diaper dermatitis in the United States. Arch Pediatr Adolesc Med 154(9):943–946PubMedCrossRefGoogle Scholar
  27. 27.
    Fan X, Xiao FL, Yang S, Liu JB, Yan KL, Liang YH, Sun LD, Du WH, Jin YT, Zhang XJ (2007) Childhood psoriasis: a study of 277 patients from China. J Eur Acad Dermatol Venereol 21(6):762–765PubMedCrossRefGoogle Scholar
  28. 28.
    Kumar B, Jain R, Sandhu K, Kaur I, Handa S (2004) Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol 43(9):654–658PubMedCrossRefGoogle Scholar
  29. 29.
    Nanda A, Kaur S, Kaur I, Kumar B (1990) Childhood psoriasis – an epidemiologic survey of 112 patients. Pediatr Dermatol 7(1):19–21PubMedCrossRefGoogle Scholar
  30. 30.
    Seyhan M, Coskun BK, Saglam H, Ozcan H, Karincaoglu Y (2006) Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int 48(6):525–530PubMedCrossRefGoogle Scholar
  31. 31.
    Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis D (2005) Prevalence and treatment of psoriasis in the United Kingdom – a population-based study. Arch Dermatol 141(12):1537–1541PubMedCrossRefGoogle Scholar
  32. 32.
    Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schaefer I (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636PubMedCrossRefGoogle Scholar
  33. 33.
    Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S (1989) Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl 146:178–179Google Scholar
  34. 34.
    Braathen LR, Botten G, Bjerkedal T (1989) Psoriatics in Norway – a questionnaire study on health-status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol Suppl (Stockh) 142:9–12Google Scholar
  35. 35.
    Brandrup F, Green A (1981) The prevalence of psoriasis in Denmark. Acta Derm Venereol 61(4):344–346PubMedGoogle Scholar
  36. 36.
    Falk ES, Vandbakk O (1993) Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh) 182:6–9Google Scholar
  37. 37.
    Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52(1):23–26PubMedCrossRefGoogle Scholar
  38. 38.
    Kavli G, Forde OH, Arnesen E, Stenvold SE (1985) Psoriasis – familial predisposition and environmental-factors. Br Med J 291(6501):999–1000CrossRefGoogle Scholar
  39. 39.
    Kavli G, Stenvold SE, Vandbakk O (1985) Low prevalence of psoriasis in Norwegian Lapps. Acta Derm Venereol 65(3):262–263PubMedGoogle Scholar
  40. 40.
    Koo J (1996) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14(3):485–496PubMedCrossRefGoogle Scholar
  41. 41.
    Lindegard B (1986) Diseases associated with psoriasis in a general-population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172(6):298–304PubMedCrossRefGoogle Scholar
  42. 42.
    Lomholt G (1964) Prevalence of skin diseases in a population; a census study from the Faroe Islands. Dan Med Bull 11:1–7PubMedGoogle Scholar
  43. 43.
    Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C (2004) Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 208(1):38–42PubMedCrossRefGoogle Scholar
  44. 44.
    Nevitt GJ, Hutchinson PE (1996) Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 135(4):533–537PubMedCrossRefGoogle Scholar
  45. 45.
    Quirk CJ (1979) Skin-disease in the Busselton population survey. Med J Aust 1(12):569–570PubMedGoogle Scholar
  46. 46.
    Rea JN, Newhouse ML, Halil T (1976) Skin-disease in Lambeth – community study of prevalence and use of medical-care. Br J Prev Soc Med 30(2):107–114PubMedCentralPubMedGoogle Scholar
  47. 47.
    Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9(2):136–139PubMedCrossRefGoogle Scholar
  48. 48.
    Yip SY (1984) The prevalence of psoriasis in the mongoloid race. J Am Acad Dermatol 10(6):965–968PubMedCrossRefGoogle Scholar
  49. 49.
    Williams H (1998) Epidemiology of skin diseases. In: Champion R, Burton J, Burns D, Breathnach S (eds) Textbook of dermatology. Blackwell Science, Oxford, pp 139–158Google Scholar
  50. 50.
    Beasley R, Keil U, von Mutius E, Pearce N, Ait-Khaled N, Anabwani G, Anderson HR, Asher MI, Bjorkstein B, Burr ML, Clayton TO, Crane J, Ellwood P, Lai CKW, Mallol J, Martinez FD, Mitchell EA, Montefort S, Robertson CF, Shah JR, Sibbald B, Stewart AW, Strachan DP, Weiland SK, Williams HC (1998) Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: Isaac. Lancet 351(9111):1225–1232CrossRefGoogle Scholar
  51. 51.
    Laughter D, Istvan JA, Tofte SJ, Hanifin JM (2000) The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 43(4):649–655PubMedCrossRefGoogle Scholar
  52. 52.
    Wiedersberg S, Naik A, Leopold CS, Guy RH (2009) Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability. Br J Dermatol 160(3):676–686PubMedCrossRefGoogle Scholar
  53. 53.
    Brown MB, Traynor MJ, Martin GP, Akomeah FK (2008) Transdermal drug delivery systems: skin perturbation devices. In: Jain K (ed) Methods in molecular biology. Humana Press, New JerseyGoogle Scholar
  54. 54.
    O’Regan GM, Sandilands A, McLean WHI, Irvine AD (2009) Filaggrin in atopic dermatitis. J Allergy Clin Immunol 124(3):R2–R6PubMedCrossRefGoogle Scholar
  55. 55.
    Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, Vreeken RJ, Hankemeier T, Kezic S, Wolterbeek R, Lavrijsen AP, Bouwstra JA (2012) Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res 53(12):2755–2766PubMedCrossRefGoogle Scholar
  56. 56.
    Hardman M, Byrne C (2006) Skin structural development. In: Elias P, Feingold K (eds) Skin barrier. Taylor & Francis, New YorkGoogle Scholar
  57. 57.
    Kalia YN, Nonato LB, Lund CH, Guy RH (1998) Development of skin barrier function in premature infants. J Invest Dermatol 111(2):320–326PubMedCrossRefGoogle Scholar
  58. 58.
    Cartwright RG, Cartlidge PHT, Rutter N, Melia CD, Davis SS (1990) Transdermal delivery of theophylline to premature-infants using a hydrogel disk system. Br J Clin Pharmacol 29(5):533–539PubMedCrossRefGoogle Scholar
  59. 59.
    Coureau B, Bussieres J-F, Tremblay S (2008) Cushing’s syndrome induced by misuse of moderate- to high-potency topical corticosteroids. Ann Pharmacother 42(12):1903–1907PubMedCrossRefGoogle Scholar
  60. 60.
    Singal A, Thami GP (2006) Lindane neurotoxicity in childhood. Am J Ther 13(3):277–280PubMedCrossRefGoogle Scholar
  61. 61.
    Zhai HB, Meier-Davis SR, Cayme B, Shudo J, Maibach H (2012) Irritant contact dermatitis: effect of age. Cutan Ocul Toxicol 31(2):138–143PubMedCrossRefGoogle Scholar
  62. 62.
    Wester R, Maibach H (2005) Regional variation in percutaneous absorption: principles and applications to human risk assessment. In: Bronaugh RL, Maibach HI (eds) Percutaneous absorption drugs – cosmetics – mechanisms – methodology, 4th edn. Taylor & Francis Group, Boca Raton, pp 85–93CrossRefGoogle Scholar
  63. 63.
    Ogiso T, Shiraki T, Okajima K, Tanino T, Iwaki M, Wada T (2002) Transfollicular drug delivery: penetration of drugs through human scalp skin and comparison of penetration between scalp and abdominal skins in vitro. J Drug Target 10(5):369–378PubMedCrossRefGoogle Scholar
  64. 64.
    Ortiz PG, Hansen SH, Shah VP, Menne T, Benfeldt E (2009) Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol 89(1):33–38Google Scholar
  65. 65.
    Ozon A, Cetinkaya S, Alikasifoglu A, Gonc EN, Sen Y, Kandemir N (2007) Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 20(2):219–225PubMedCrossRefGoogle Scholar
  66. 66.
    Gould AR, Sharp PJ, Smith DR, Stegink AJ, Chase CJ, Kovacs JC, Penglis S, Chatterton BE, Bunn CL (2003) Increased permeability of psoriatic skin to the protein, plasminogen activator inhibitor 2. Arch Dermatol Res 295(6):249–254PubMedCrossRefGoogle Scholar
  67. 67.
    Singh P, Roberts MS (1994) Skin permeability and local tissue concentrations of nonsteroidal antiinflammatory drugs after topical application. J Pharmacol Exp Ther 268(1):144–151PubMedGoogle Scholar
  68. 68.
    Magnusson BM, Pugh WJ, Roberts MS (2004) Simple rules defining the potential of compounds for transdermal delivery or toxicity. Pharm Res 21(6):1047–1054PubMedCrossRefGoogle Scholar
  69. 69.
    Reid ML, Jones SA, Brown MB (2009) Transient drug supersaturation kinetics of beclomethasone dipropionate in rapidly drying films. Int J Pharm 371(1–2):114–119PubMedCrossRefGoogle Scholar
  70. 70.
    Stoughton RB, Wullich K (1989) The same glucocorticoid in brand-name products – does increasing the concentration result in greater topical biologic activity. Arch Dermatol 125(11):1509–1511PubMedCrossRefGoogle Scholar
  71. 71.
    British National Formulary 65 (2013) British Medical Association and the Royal Pharmaceutical Society of Great Britain, LondonGoogle Scholar
  72. 72.
    Trottet L, Owen H, Holme P, Heylings J, Collin IP, Breen AP, Siyad MN, Nandra RS, Davis AF (2005) Are all aciclovir cream formulations bioequivalent? Int J Pharm 304(1–2):63–71PubMedCrossRefGoogle Scholar
  73. 73.
    Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH (2001) Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm 219(1–2):11–19PubMedCrossRefGoogle Scholar
  74. 74.
    Williams AC, Barry BW (2004) Penetration enhancers. Adv Drug Deliv Rev 56(5):603–618PubMedCrossRefGoogle Scholar
  75. 75.
    Lee PJ, Ahmad N, Langer R, Mitragotri S, Shastri VP (2006) Evaluation of chemical enhancers in the transdermal delivery of lidocaine. Int J Pharm 308(1–2):33–39PubMedCrossRefGoogle Scholar
  76. 76.
    Sato K, Sugibayashi K, Morimoto Y (1988) Effect and mode of action of aliphatic esters on the in vitro skin permeation of nicorandil. Int J Pharm 43(1–2):31–40CrossRefGoogle Scholar
  77. 77.
    Hollingsbee DA, Fairbrother JE, Martin GP, Marriott C, Monger L (1991) The effect of a hydrocolloid dermatological patch (actiderm) in potentiating the skin blanching activity of triamcinolone acetonide. Int J Pharm 77(2–3):199–209CrossRefGoogle Scholar
  78. 78.
    Pershing LK, Silver BS, Krueger GG, Shah VP, Skelley JP (1992) Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm Res 9(1):45–51PubMedCrossRefGoogle Scholar
  79. 79.
    Curdy C, Naik A, Kalia YN, Alberti I, Guy RH (2004) Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo. Int J Pharm 271(1–2):251–256PubMedCrossRefGoogle Scholar
  80. 80.
    National Psoriasis Foundation (2009) Topical treatments for psoriasis, including steroids. http://www.psoriasis.org/document.doc?id=164
  81. 81.
    Gupta G, Mallefet P, Kress DW, Sergeant A (2009) Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol 161(2):221–227PubMedCrossRefGoogle Scholar
  82. 82.
    Ellis RM, Koch LH, McGuire E, Williams JV (2011) Potential barriers to adherence in pediatric dermatology. Pediatr Dermatol 28(3):242–244PubMedCrossRefGoogle Scholar
  83. 83.
    Arzhavitina A, Steckel H (2010) Foams for pharmaceutical and cosmetic application. Int J Pharm 394(1–2):1–17PubMedCrossRefGoogle Scholar
  84. 84.
    Andreassi L, Giannetti A, Milani M (2003) Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 148(1):134–138PubMedCrossRefGoogle Scholar
  85. 85.
    Lloyd A, Hodgkins P, Dewilde S, Sasane R, Falconer S, Barke ES (2011) Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. Int J Technol Assess Health Care 27(3):215–223PubMedCrossRefGoogle Scholar
  86. 86.
    Zernikow B, Michel E, Anderson B (2007) Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 8(3):187–207PubMedCrossRefGoogle Scholar
  87. 87.
    Teske J, Weller J-P, Larsch K, Troeger HD, Karst M (2007) Fatal outcome in a child after ingestion of a transdermal fentanyl patch. Int J Leg Med 121(2):147–151CrossRefGoogle Scholar
  88. 88.
    Wokovich AM, Shen M, Doub WH, Machado SG, Buhse LF (2011) Evaluating elevated release liner adhesion of a transdermal drug delivery system (TDDS): a study of Daytrana methylphenidate transdermal system. Drug Dev Ind Pharm 37(10):1217–1224PubMedCrossRefGoogle Scholar
  89. 89.
    Effendy I, Maibach HI (1996) Detergent and skin irritation. Clin Dermatol 14(1):15–21PubMedCrossRefGoogle Scholar
  90. 90.
    Cork M, Timmins J, Holden C, Carr J, Berry V, Tazi-Ahnini R, Ward S (2003) An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharm J 271:747–748Google Scholar
  91. 91.
    Tsang M, Guy RH (2010) Effect of aqueous cream BP on human stratum corneum in vivo. Br J Dermatol 163(5):954–958PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  • William J. McAuley
    • 1
  • Matthew Traynor
    • 1
  • Marc B. Brown
    • 2
    • 3
  1. 1.Department of Pharmacy, School of Life and Medical SciencesUniversity of HertfordshireHatfieldUK
  2. 2.Department of PharmacyUniversity of HertfordshireHatfieldUK
  3. 3.R&D Centre, MedPharm LtdGuilfordUK

Personalised recommendations